Exyte, a global powerhouse in high-tech facility engineering, has announced a significant leap forward in the biotech and pharmaceutical sectors by finalising its acquisition of TTP Group, a major player in engineering solutions for blue-chip clients across Europe. The acquisition, originally disclosed in September 2024, received the necessary regulatory clearances and is now officially complete, positioning Exyte for ambitious growth in the competitive European life sciences and biotech markets.
TTP Group, renowned for its specialised services under the established Pharmaplan and Triplan brands, provides end-to-end support in engineering, procurement, and construction management (EPCM) for high-value clients in the biotech, pharmaceutical, and chemical industries. By integrating TTP’s expertise, Exyte aims to offer a more comprehensive suite of services, spanning from strategic planning to full facility delivery, allowing the company to deepen its footprint in the fast-evolving biotech and pharma industries in Europe.
Exyte’s CEO, Dr. Wolfgang Büchele, emphasised the acquisition as a major step on the company’s “Pathway to Ten” initiative, a core element of its future roadmap, “Next Level.” “With TTP on board, Exyte not only gains advanced engineering capabilities but also strengthens our market leadership in Europe,” Büchele said. “Together, we can now deliver even greater support to our European clients, meeting the rising demand for sustainable, state-of-the-art facilities in the life sciences sector.”
TTP Group CEO Dr. Andreas Bonhoff echoed the sentiment, noting that both companies share a commitment to sustainability and innovation in facility solutions. “The union of TTP and Exyte provides enhanced services for our clients while fostering growth in the high-demand market for pharmaceutical facilities. This partnership is a strong step toward a prosperous future,” Bonhoff stated.
Scaling Biopharma & Life Sciences
The acquisition is also a boost to Exyte’s Biopharma and Life Sciences business unit, the company’s second-largest segment by revenue, which reached €580 million in 2023 with an order intake increase of 12 percent to €650 million. With the integration of TTP, Exyte expects this business unit to play an increasingly central role in the company’s growth, with a medium-term goal of reaching €1.5 billion in sales. Ronan Donohue, President of Exyte’s Biopharma and Life Sciences unit, views TTP’s expertise as a “key accelerator” for achieving these ambitious goals, underscoring Exyte’s drive to become a go-to provider for Europe’s biotech industry.
This latest acquisition not only supports Exyte’s long-term growth objectives but reinforces its standing as a global leader in ultra-clean and sustainable facilities across key industries like semiconductors, battery cells, and, increasingly, pharmaceuticals and biotechnology. With nearly 10,000 employees worldwide and an annual revenue of €7.1 billion in 2023, Exyte continues to redefine its industry by advancing high-quality, sustainable solutions that enable modern life and contribute to a healthier future.
As Exyte and TTP embark on this new chapter, the combined strengths of both firms promise a unique offering for clients navigating Europe’s burgeoning biotech landscape, cementing Exyte’s role as a leading force in life sciences infrastructure across the continent.
